[
  {
    "ts": null,
    "headline": "Citi Maintains a Hold Rating on Pfizer (PFE) Amidst Pricing Policy Headwinds",
    "summary": "On May 21, analyst Geoff Meacham of Citi maintained a Hold rating on Pfizer Inc. (NYSE:PFE), reiterating the price target of $25. The analyst acknowledged the strong Q1 2025 performance of the company. However, he remains cautious due to the potential Most Favored Nation (MFN) pricing policy headwinds. The Most Favored Nation (MFN) pricing policy […]",
    "url": "https://finnhub.io/api/news?id=36a9e51529adf656300253c0b2ecbfa2a56d82f6abb552c5244457db47a9def2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747859573,
      "headline": "Citi Maintains a Hold Rating on Pfizer (PFE) Amidst Pricing Policy Headwinds",
      "id": 134648052,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "On May 21, analyst Geoff Meacham of Citi maintained a Hold rating on Pfizer Inc. (NYSE:PFE), reiterating the price target of $25. The analyst acknowledged the strong Q1 2025 performance of the company. However, he remains cautious due to the potential Most Favored Nation (MFN) pricing policy headwinds. The Most Favored Nation (MFN) pricing policy […]",
      "url": "https://finnhub.io/api/news?id=36a9e51529adf656300253c0b2ecbfa2a56d82f6abb552c5244457db47a9def2"
    }
  },
  {
    "ts": null,
    "headline": "Bernstein Reaffirms Pfizer Rating After $6B Cancer Treatment Deal",
    "summary": "Bernstein analysts reaffirmed their Market Perform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on May 20, following the company’s recently disclosed $6 billion licensing deal with 3SBio Inc. to develop and market the cancer treatment SSGJ-707. While a notable venture at face value, the deal has raised questions about Pfizer’s continued collaboration with […]",
    "url": "https://finnhub.io/api/news?id=e21f323a759c01ee81def62d47c06dd0667399318896ed040017048e5cdb9142",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747851724,
      "headline": "Bernstein Reaffirms Pfizer Rating After $6B Cancer Treatment Deal",
      "id": 134628530,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Bernstein analysts reaffirmed their Market Perform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on May 20, following the company’s recently disclosed $6 billion licensing deal with 3SBio Inc. to develop and market the cancer treatment SSGJ-707. While a notable venture at face value, the deal has raised questions about Pfizer’s continued collaboration with […]",
      "url": "https://finnhub.io/api/news?id=e21f323a759c01ee81def62d47c06dd0667399318896ed040017048e5cdb9142"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=ea84577a0b125915f0d06d57c7eea7d6476e037b52c4bbbe0f48963ef49f9981",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747845420,
      "headline": "Pfizer Inc. stock underperforms Wednesday when compared to competitors",
      "id": 134635641,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=ea84577a0b125915f0d06d57c7eea7d6476e037b52c4bbbe0f48963ef49f9981"
    }
  },
  {
    "ts": null,
    "headline": "Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' May Dividend Dogs",
    "summary": "My monthly update and commentary on the top dividend stock picks from the Barron's Better Bets list, May 2025 edition. Read the full report here on Seeking Alpha.",
    "url": "https://finnhub.io/api/news?id=95a503837c6b91b8e77bef1cec029fc38a347eaad7cfe9cc432a06e675bd267b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747844404,
      "headline": "Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' May Dividend Dogs",
      "id": 134629807,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157307764/image_157307764.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "My monthly update and commentary on the top dividend stock picks from the Barron's Better Bets list, May 2025 edition. Read the full report here on Seeking Alpha.",
      "url": "https://finnhub.io/api/news?id=95a503837c6b91b8e77bef1cec029fc38a347eaad7cfe9cc432a06e675bd267b"
    }
  },
  {
    "ts": null,
    "headline": "Home Depot backs outlook as U.S. sales ticked up: Morning Buzz",
    "summary": "Stocks are lower at midday, putting in jeopardy the six-day winning streak for the S&P 500. Federal Reserve officials’ commentary is anticipated to provide insights into the central bank’s outlook on inflation and interest rates, while markets continue digesting the implications of Moody’s recent downgrade of the U.S. sovereign credit rating, which has heightened concerns about the nation’s fiscal health as lawmakers debate President Trump’s “big, beautiful” tax bill. Looking ahead, investors ar",
    "url": "https://finnhub.io/api/news?id=b469a23af7f9ffd1a20508b5a9d6102382968ad15c15f92e312b5daed9c6761f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747842934,
      "headline": "Home Depot backs outlook as U.S. sales ticked up: Morning Buzz",
      "id": 134627966,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Stocks are lower at midday, putting in jeopardy the six-day winning streak for the S&P 500. Federal Reserve officials’ commentary is anticipated to provide insights into the central bank’s outlook on inflation and interest rates, while markets continue digesting the implications of Moody’s recent downgrade of the U.S. sovereign credit rating, which has heightened concerns about the nation’s fiscal health as lawmakers debate President Trump’s “big, beautiful” tax bill. Looking ahead, investors ar",
      "url": "https://finnhub.io/api/news?id=b469a23af7f9ffd1a20508b5a9d6102382968ad15c15f92e312b5daed9c6761f"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Pfizer, Coca-Cola and The Walt Disney",
    "summary": "Pfizer, Coca-Cola and The Walt Disney are part of the Zacks top Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=0864d71f80b794effd3b7f6b6906181584a455bcf06529084efe84501b7bb5f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747832880,
      "headline": "The Zacks Analyst Blog Highlights Pfizer, Coca-Cola and The Walt Disney",
      "id": 134628245,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer, Coca-Cola and The Walt Disney are part of the Zacks top Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=0864d71f80b794effd3b7f6b6906181584a455bcf06529084efe84501b7bb5f9"
    }
  },
  {
    "ts": null,
    "headline": "MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots",
    "summary": "Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.",
    "url": "https://finnhub.io/api/news?id=d866fc2c60d7383f41a105c56a069473e22496474dba66a57c93baf0687b1d0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747831020,
      "headline": "MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots",
      "id": 134628535,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.",
      "url": "https://finnhub.io/api/news?id=d866fc2c60d7383f41a105c56a069473e22496474dba66a57c93baf0687b1d0b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Looks Like A Great Play At Current Valuations",
    "summary": "Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals versus peers.",
    "url": "https://finnhub.io/api/news?id=a926781e85b4794d8dfc4b02946c645e3c548a2b3de04af57250c83422ef2b47",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747830005,
      "headline": "Pfizer Looks Like A Great Play At Current Valuations",
      "id": 134626678,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359138081/image_1359138081.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals versus peers.",
      "url": "https://finnhub.io/api/news?id=a926781e85b4794d8dfc4b02946c645e3c548a2b3de04af57250c83422ef2b47"
    }
  },
  {
    "ts": null,
    "headline": "The Play On BridgeBio Pharma: Great Expectations For Attruby",
    "summary": "The Play On BridgeBio Pharma: Great Expectations For Attruby",
    "url": "https://finnhub.io/api/news?id=b7e0b5a551d688d00b13533cc90a274d2ee677a07cd70a1c24638e9d24522b0e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747828935,
      "headline": "The Play On BridgeBio Pharma: Great Expectations For Attruby",
      "id": 134626604,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b7e0b5a551d688d00b13533cc90a274d2ee677a07cd70a1c24638e9d24522b0e"
    }
  },
  {
    "ts": null,
    "headline": "Giant US companies are rushing to Europe to borrow money",
    "summary": "(Bloomberg) -- The giants of corporate America from Pfizer Inc. to Alphabet Inc. are borrowing in euros like never before as the anxiety triggered by President Donald Trump’s tariff threats pushes them to hunt for alternative funding avenues in case their home market freezes up.Most Read from BloombergCan Frank Gehry’s ‘Grand LA’ Make Downtown Feel Like a Neighborhood?Chicago’s O’Hare Airport Seeks Up to $4.3 Billion of Muni DebtNJ Transit Makes Deal With Engineers, Ending Three-Day StrikeA reco",
    "url": "https://finnhub.io/api/news?id=e41564ec69f52e28212474facc21b765a2a70e9d78778404be2aea7c5e5fb2c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747825224,
      "headline": "Giant US companies are rushing to Europe to borrow money",
      "id": 134628236,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- The giants of corporate America from Pfizer Inc. to Alphabet Inc. are borrowing in euros like never before as the anxiety triggered by President Donald Trump’s tariff threats pushes them to hunt for alternative funding avenues in case their home market freezes up.Most Read from BloombergCan Frank Gehry’s ‘Grand LA’ Make Downtown Feel Like a Neighborhood?Chicago’s O’Hare Airport Seeks Up to $4.3 Billion of Muni DebtNJ Transit Makes Deal With Engineers, Ending Three-Day StrikeA reco",
      "url": "https://finnhub.io/api/news?id=e41564ec69f52e28212474facc21b765a2a70e9d78778404be2aea7c5e5fb2c0"
    }
  },
  {
    "ts": null,
    "headline": "2 High-Yield Dividend Stocks to Buy Right Now",
    "summary": "Pfizer can get out of its recent troubles thanks to a deep pipeline and cost-cutting efforts.  Medical Properties Trust has made tremendous progress in overcoming its recent obstacles.  Consider that the average dividend yield for the S&P 500 (SNPINDEX: ^GSPC) is 1.3%, which is not particularly high.",
    "url": "https://finnhub.io/api/news?id=a7397839b0ba7f1ebb274937d1577060cf08e1846e8fcc27afd12456b9cb440e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747822980,
      "headline": "2 High-Yield Dividend Stocks to Buy Right Now",
      "id": 134628540,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer can get out of its recent troubles thanks to a deep pipeline and cost-cutting efforts.  Medical Properties Trust has made tremendous progress in overcoming its recent obstacles.  Consider that the average dividend yield for the S&P 500 (SNPINDEX: ^GSPC) is 1.3%, which is not particularly high.",
      "url": "https://finnhub.io/api/news?id=a7397839b0ba7f1ebb274937d1577060cf08e1846e8fcc27afd12456b9cb440e"
    }
  },
  {
    "ts": null,
    "headline": "PFIZER INC : Jefferies remains its Buy rating",
    "summary": "Already positive, the research from Jefferies and its analyst Akash Tewari still consider the stock as a Buy opportunity. The target price is revised upwards from USD 33 to USD 32.",
    "url": "https://finnhub.io/api/news?id=514f1ba4ada1bfd893538815326d5c6713508a96191e3c9903864006687c17d3",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747822152,
      "headline": "PFIZER INC : Jefferies remains its Buy rating",
      "id": 134625567,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Already positive, the research from Jefferies and its analyst Akash Tewari still consider the stock as a Buy opportunity. The target price is revised upwards from USD 33 to USD 32.",
      "url": "https://finnhub.io/api/news?id=514f1ba4ada1bfd893538815326d5c6713508a96191e3c9903864006687c17d3"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Loses Patent Suit Against South Korean Vaccine Maker",
    "summary": "By Dean Seal South Korean vaccine company SK Bioscience said it has prevailed in a lawsuit brought by Pfizer that accused it of infringing on the patent for the drugmaker's Prevnar 13 vaccine. ...",
    "url": "https://finnhub.io/api/news?id=3198c80165bf1d30b77a4b172fece6a9b1660d6c44a59737f2c0b66a4ded86d3",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747817709,
      "headline": "Pfizer Loses Patent Suit Against South Korean Vaccine Maker",
      "id": 134625024,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "By Dean Seal South Korean vaccine company SK Bioscience said it has prevailed in a lawsuit brought by Pfizer that accused it of infringing on the patent for the drugmaker's Prevnar 13 vaccine. ...",
      "url": "https://finnhub.io/api/news?id=3198c80165bf1d30b77a4b172fece6a9b1660d6c44a59737f2c0b66a4ded86d3"
    }
  },
  {
    "ts": null,
    "headline": "SK Bioscience - Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine",
    "summary": "SK Bioscience Co Ltd: * SK BIOSCIENCE CO LTD - WINS PATENT LAWSUIT AGAINST PFIZEROVERPNEUMOCOCCAL VACCINE * SK BIOSCIENCE CO- FROM 2027, WILL BE ABLE TO...",
    "url": "https://finnhub.io/api/news?id=3a6893f55363b1dde0a68f47b85fa08b90d83bf3f1e535a38b0e249c23c84157",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747817538,
      "headline": "SK Bioscience - Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine",
      "id": 134625009,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "SK Bioscience Co Ltd: * SK BIOSCIENCE CO LTD - WINS PATENT LAWSUIT AGAINST PFIZEROVERPNEUMOCOCCAL VACCINE * SK BIOSCIENCE CO- FROM 2027, WILL BE ABLE TO...",
      "url": "https://finnhub.io/api/news?id=3a6893f55363b1dde0a68f47b85fa08b90d83bf3f1e535a38b0e249c23c84157"
    }
  },
  {
    "ts": null,
    "headline": "My Dividend Stock Portfolio: New All-Time Dividend Record In April - 100 Holdings With 14 Buys",
    "summary": "My Dividend Stock Portfolio: New All-Time Dividend Record In April - 100 Holdings With 14 Buys",
    "url": "https://finnhub.io/api/news?id=da857ba038502fb2801876c07073c96e54676960374534733580830e88991dab",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747815000,
      "headline": "My Dividend Stock Portfolio: New All-Time Dividend Record In April - 100 Holdings With 14 Buys",
      "id": 134624799,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=da857ba038502fb2801876c07073c96e54676960374534733580830e88991dab"
    }
  }
]